Education
About Us
Working with TipRanks
Follow Us
Amphastar Pharmaceuticals (AMPH)
NASDAQ:AMPH
RESEARCH TOOLSreports
Earnings Data
Report Date
Aug 11, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.74Last Year’s EPS
0.94Same Quarter Last Year
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 07, 2025
|% Change Since: -0.37%
|Next Earnings Date:Aug 11, 2025
Earnings Call Sentiment|Neutral
The earnings call revealed a mixed performance with notable achievements in product sales growth and strategic partnerships, but also significant challenges in revenue decline and increased competition affecting key products like Glucagon and Epinephrine. Operational efficiency measures and pipeline progress provide optimism for the future, but current financial pressures and competition present ongoing challenges.Company Guidance
During Amphastar Pharmaceuticals' first quarter earnings call for fiscal year 2025, the management provided guidance on several key metrics and strategic initiatives. The company reported net revenues of $170.5 million, marking a 1% decrease from the previous year. BAQSIMI achieved sales of $38.3 million in the first quarter, nearly matching the combined sales of this product by Lilly and Amphastar from the prior year. Primatene MIST sales rose 20% to $29 million, driven by increased unit volumes and expanded physician outreach. Despite competitive pressures leading to a 27% decline in Glucagon injection sales to $20.8 million and a 29% decrease in Epinephrine sales to $18.6 million, Amphastar remains optimistic about its long-term growth prospects. The company continues to focus on expanding its branded product portfolio and anticipates that BAQSIMI and Primatene MIST will drive revenue growth throughout 2025. Furthermore, Amphastar is actively pursuing several pipeline opportunities, with an emphasis on capturing near-term growth through strategic FDA filings and responses. The company is also preparing for potential impacts from tariff policies but believes its U.S.-based manufacturing operations position it favorably.Drug Shortage Assistance Award
Amphastar received the Drug Shortage Assistance Award from the USFDA for its efforts in preventing critical drug shortages.
BAQSIMI Sales Growth
BAQSIMI sales grew 177% to $38.4 million compared to $13.8 million in the prior year period, reflecting Amphastar's full control over distribution.
Primatene MIST Sales Increase
Sales of Primatene MIST increased by 20% to $29 million, attributed to increased unit volumes and demand.
Pipeline Progress
The FDA accepted a Biologics License Application for AMP-004, with a BsUFA goal date in Q1 2026, marking a milestone in expanding biosimilar insulin offerings.
Operational Efficiency Measures
Amphastar is implementing cost-efficient strategies to combat margin pressures and enhance operational effectiveness.
---
AMPH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AMPH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2025 | $24.43 | $24.65 | +0.90% |
Feb 27, 2025 | $31.49 | $28.43 | -9.72% |
Nov 06, 2024 | $53.40 | $46.09 | -13.69% |
Aug 07, 2024 | $38.89 | $44.06 | +13.29% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Amphastar Pharmaceuticals (AMPH) report earnings?
Amphastar Pharmaceuticals (AMPH) is schdueled to report earning on Aug 11, 2025, TBA Not Confirmed.
What is Amphastar Pharmaceuticals (AMPH) earnings time?
Amphastar Pharmaceuticals (AMPH) earnings time is at Aug 11, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AMPH EPS forecast?
AMPH EPS forecast for the fiscal quarter 2025 (Q2) is 0.74.
---